J J O'Byrne1, S A Lynch2, E P Treacy3, M D King4, D R Betts2, P D Mayne5, F Sharif6. 1. Department of Clinical Genetics, Our Lady's Children's Hospital, Crumlin, Dublin 12, Ireland. obyrnej@tcd.ie. 2. Department of Clinical Genetics, Our Lady's Children's Hospital, Crumlin, Dublin 12, Ireland. 3. National Centre for Inherited Metabolic Disorders, Temple Street Children's University Hospital, Dublin 1, Ireland. 4. Department of Neurology, Temple Street Children's University Hospital, Dublin 1, Ireland. 5. Department of Biochemistry, Temple Street Children's University Hospital, Dublin 1, Ireland. 6. Department of Paediatrics, Midland Regional Hospital, Mullingar, Co. Westmeath, Ireland.
Abstract
BACKGROUND: Investigation of patients, particularly children, with unexplained global developmental delay (GDD)/learning disability (LD) has been challenging due to a lack of clear guidance from specialised centres. Limited knowledge of rare diseases and a poor understanding of the purpose or limitations of appropriate investigations have been some of the principal reasons for this difficulty. AIMS: A guideline development group was formed to recommend on appropriate, first line metabolic, genetic and radiological investigations for children and adults with unexplained GDD/ID. METHODS AND RECOMMENDATIONS: A comprehensive literature search was conducted, evaluated and reviewed by the guideline committee and a best practice protocol for first line assessment and genetic, metabolic and radiological investigations was decided upon after considering diagnostic yield, practicality, treatability and costs. CONCLUSION: It is hoped that these recommendations will become national guidelines for the first line metabolic, genetic and radiological investigation of patients presenting with unexplained GDD/ID.
BACKGROUND: Investigation of patients, particularly children, with unexplained global developmental delay (GDD)/learning disability (LD) has been challenging due to a lack of clear guidance from specialised centres. Limited knowledge of rare diseases and a poor understanding of the purpose or limitations of appropriate investigations have been some of the principal reasons for this difficulty. AIMS: A guideline development group was formed to recommend on appropriate, first line metabolic, genetic and radiological investigations for children and adults with unexplained GDD/ID. METHODS AND RECOMMENDATIONS: A comprehensive literature search was conducted, evaluated and reviewed by the guideline committee and a best practice protocol for first line assessment and genetic, metabolic and radiological investigations was decided upon after considering diagnostic yield, practicality, treatability and costs. CONCLUSION: It is hoped that these recommendations will become national guidelines for the first line metabolic, genetic and radiological investigation of patients presenting with unexplained GDD/ID.
Entities:
Keywords:
First line investigations; Global developmental delay; Guidelines; Learning disability
Authors: Jessica Hunter; Oliver Rivero-Arias; Angel Angelov; Edward Kim; Iain Fotheringham; Jose Leal Journal: Am J Med Genet A Date: 2014-04-03 Impact factor: 2.802
Authors: David T Miller; Margaret P Adam; Swaroop Aradhya; Leslie G Biesecker; Arthur R Brothman; Nigel P Carter; Deanna M Church; John A Crolla; Evan E Eichler; Charles J Epstein; W Andrew Faucett; Lars Feuk; Jan M Friedman; Ada Hamosh; Laird Jackson; Erin B Kaminsky; Klaas Kok; Ian D Krantz; Robert M Kuhn; Charles Lee; James M Ostell; Carla Rosenberg; Stephen W Scherer; Nancy B Spinner; Dimitri J Stavropoulos; James H Tepperberg; Erik C Thorland; Joris R Vermeesch; Darrel J Waggoner; Michael S Watson; Christa Lese Martin; David H Ledbetter Journal: Am J Hum Genet Date: 2010-05-14 Impact factor: 11.025
Authors: A García-Cazorla; N I Wolf; M Serrano; U Moog; B Pérez-Dueñas; P Póo; M Pineda; J Campistol; G F Hoffmann Journal: J Inherit Metab Dis Date: 2009-08-14 Impact factor: 4.982
Authors: Elliott H Sherr; David J Michelson; Michael I Shevell; John B Moeschler; Andrea L Gropman; Stephen Ashwal Journal: Ann Neurol Date: 2013-08 Impact factor: 11.274